Rinat Rotem‐Yehudar
Publications by Year
Research Areas
Cancer Immunotherapy and Biomarkers, Immune Cell Function and Interaction, Immunotherapy and Immune Responses, CAR-T cell therapy research, Cervical Cancer and HPV Research
Most-Cited Works
- → The PD-1/PD-L1 axis modulates the natural killer cell versus multiple myeloma effect: a therapeutic target for CT-011, a novel monoclonal anti–PD-1 antibody(2010)798 cited
- → Phase I Safety and Pharmacokinetic Study of CT-011, a Humanized Antibody Interacting with PD-1, in Patients with Advanced Hematologic Malignancies(2008)692 cited
- → PD-1–Expressing Tumor-Infiltrating T Cells Are a Favorable Prognostic Biomarker in HPV-Associated Head and Neck Cancer(2012)629 cited
- → Safety and activity of PD1 blockade by pidilizumab in combination with rituximab in patients with relapsed follicular lymphoma: a single group, open-label, phase 2 trial(2013)529 cited
- → Disabling Immune Tolerance by Programmed Death-1 Blockade With Pidilizumab After Autologous Hematopoietic Stem-Cell Transplantation for Diffuse Large B-Cell Lymphoma: Results of an International Phase II Trial(2013)438 cited
- → PD-1 Blockade by CT-011, Anti-PD-1 Antibody, Enhances Ex Vivo T-cell Responses to Autologous Dendritic Cell/Myeloma Fusion Vaccine(2011)282 cited
- → Anti‐PD‐1 synergizes with cyclophosphamide to induce potent anti‐tumor vaccine effects through novel mechanisms(2011)145 cited
- → Association of Insulin-like Growth Factor 1 Receptor with EHD1 and SNAP29(2001)134 cited
- → LMP-associated proteolytic activities and TAP-dependent peptide transport for class 1 MHC molecules are suppressed in cell lines transformed by the highly oncogenic adenovirus 12.(1996)100 cited
- → EHD3: A Protein That Resides in Recycling Tubular and Vesicular Membrane Structures and Interacts with EHD1(2002)85 cited